Andrew Lazerow defends domestic and international clients in some of their most important antitrust litigation, including class actions and competitor disputes. In addition to his litigation practice, Mr. Lazerow regularly advises innovator pharmaceutical clients on various types of business issues, including potential settlements of Hatch-Waxman ANDA patent litigation, product life-cycle management, and REMS.
Representative Matters
- Defended AstraZeneca in consolidated class action litigation involving allegations of unlawful settlements of Hatch-Waxman ANDA patent litigation. Achieved favorable trial outcome.
- Defended Valeant Pharmaceuticals in consolidated class action litigation involving allegations of sham litigation. Achieved settlement after win on summary judgment.
- Defending innovator pharmaceutical company in consolidated class action litigation involving allegations of unlawful settlements of Hatch-Waxman ANDA patent litigation.
- Defending Citigroup in class actions involving antitrust and commodities fraud claims relating to alleged manipulation of financial benchmarks, including foreign currency exchange benchmarks and ISDAFIX®.
- Defending JPMorgan in antitrust class actions and competitor actions involving alleged boycott of electronic exchanges for trading interest rate swaps.
